Foghorn Therapeutics Newsroom

Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines and Montai Therapeutics Under Its Strategic Partnership With Pfizer

PR Newswire19minutes ago

Foghorn Therapeutics (FHTX) Collaborates With Eli Lilly and Surpasses Q3 Expectations

TipRanksNov 13 05:47 ET

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswireNov 12 07:54 ET

Express News | Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results

BenzingaNov 5 15:51 ET

H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsNov 5 06:36 ET · Ratings

TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating

Moomoo NewsNov 4 19:33 ET · Ratings

TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)

TipRanksNov 4 19:16 ET · Ratings

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Zacks Nov 4 16:45 ET

Express News | Foghorn Therapeutics Inc.: Cash, Cash Equivalents, and Marketable Securities of $267.4 Mln as of September 30, 2024, Provides Cash Runway Into 2027

ReutersNov 4 16:31 ET

Foghorn Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 4 16:22 ET · Announcements

Press Release: Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Dow JonesNov 4 16:05 ET

Express News | Foghorn Therapeutics Q3 Net Income USD -19.122 Million

ReutersNov 4 16:05 ET

Express News | Foghorn Therapeutics Q3 Collaboration Revenue USD 7.808 Million

ReutersNov 4 16:05 ET

Express News | Foghorn Therapeutics Q3 EPS USD -0.31

ReutersNov 4 16:05 ET

Express News | Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

ReutersOct 23 08:00 ET

Press Release: Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Dow JonesOct 23 08:00 ET

More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 28%

Simply Wall StOct 22 06:43 ET

Foghorn Therapeutics Unveils Clinical Pipeline Progress

TipRanksOct 10 07:47 ET

Express News | Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral Smarca2 Selective Inhibitor Fhd-909 in a Phase 1 Trial for Smarca4 Mutated Solid Tumors

ReutersOct 10 07:00 ET

Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Yahoo FinanceOct 10 07:00 ET